In general, as someone without diabetes, you want your fasting blood sugar (when you haven’t eaten for at least eight hours) to be below 100 mg/dL. You want your spikes to be below 180 mg/dL, to lower ...
Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...
Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous ...
Senseonics announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark approval.
Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...
DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2025 revenue of roughly US$4.66 billion, both rising at double-digit ...
The manufacturer has identified that certain Abiomed heart pumps with differential pressure sensors have the potential to ...
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter ...
DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to Underweight from Equal Weight with a price target of $71, which was brought ...
Abbott Diabetes Care has recalled some of its FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitor sensors for people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results